Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report issued on Monday. The brokerage set a “sell” rating on the stock.

A number of other analysts have also issued reports on the stock. Maxim Group dropped their price objective on shares of Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 26th. Roth Mkm reiterated a “buy” rating and set a $40.00 price objective on shares of Moleculin Biotech in a research note on Friday, April 12th.

Moleculin Biotech Stock Up 0.2 %

Shares of MBRX stock opened at $5.02 on Monday. The stock has a market cap of $11.19 million, a price-to-earnings ratio of -0.37 and a beta of 1.96. Moleculin Biotech has a fifty-two week low of $4.28 and a fifty-two week high of $15.75. The firm’s 50 day moving average price is $6.59 and its two-hundred day moving average price is $8.01.

Institutional Trading of Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Atticus Wealth Management LLC purchased a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned about 0.17% of Moleculin Biotech at the end of the most recent quarter. 15.52% of the stock is currently owned by institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.